| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Med. & Reg. Officer | Chief Medical Officer | Chief Medical & Reg. Officer
1 company
Gary Ingenito last filed a Form 4 in May 2025, as Chief Med. & Reg. Officer at CPRX. Gary Ingenito's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Gary Ingenito's trades have earned a below-average insider score of 49/100 across 11 rated trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -15.4%.
At the last filing, the largest reported position was 68,873 shares of CPRX. The CPRX filings lean toward selling, a net 897,918 shares.
Gary Ingenito has 18 Form 4 filings on record from September 2022 to May 2025, all as Chief Med. & Reg. Officer at Catalyst Pharmaceuticals (CPRX), 2022–2025.
The 43 reported transactions were 18 option exercises, 13 open-market sales, 6 tax withholdings and 6 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 9 sales worth about $17.9M.
The largest open-market sale was 244,000 shares of CPRX at an average $23.67 on May 14, 2025, about $5.8M. Twelve months later CPRX was up 33%.
None of the 7 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from May 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2025 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Med. & Reg. Officer | Sale+OE | 244,000 | $23.67 | $5,775,720.00 | -78.0% | -13.1% | +33.2% | |
| Mar 6, 2025 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Med. & Reg. Officer | Sale+OE | 225,000 | $21.75 | $4,894,609.68 | -76.6% | +16.7% | +11.8% | |
| Nov 27, 2024 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Med. & Reg. Officer | Sale+OE | 12,000 | $22.72 | $272,654.28 | -18.9% | -6.9% | +4.8% | |
| Nov 20, 2024 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Med. & Reg. Officer | Sale+OE | 38,000 | $21.20 | $805,562.00 | -42.5% | +8.4% | +7.7% | |
| Aug 9, 2024 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Med. & Reg. Officer | Sale+OE | 100,000 | $18.04 | $1,804,000.00 | -66.1% | +25.8% | +7.5% | |
| Jun 5, 2024 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Med. & Reg. Officer | Sale+OE | 80,000 | $16.16 | $1,292,800.00 | -60.9% | +21.0% | +55.5% | |
| Dec 6, 2023 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Med. & Reg. Officer | Sale+OE | 50,000 | $14.02 | $701,000.00 | -56.6% | +16.1% | +54.9% | |
| Dec 6, 2022 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 5,918 | $16.85 | $99,718.30 | -16.1% | -8.3% | -14.9% | |
| Sep 14, 2022 | CPRX Catalyst Pharmaceuticals, Inc. | Chief Medical & Reg. Officer | Sale+OE | 143,000 | $15.67 | $2,241,459.00 | -86.6% | +14.7% | -17.5% |